Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Norse Atlantic Airways receives UK Air Operator Certificate and Operating Licence

Norse Atlantic Airways is pleased to announce that the UK Civil Aviation Authority has granted the airline an Air Operator Certificate (AOC) and Operating Licence (OL) allowing the company to begin direct flights from the United Kingdom.Operating direct flights from the United Kingdom has been an integral part of the Norse Atlantic Airways business plan since the inception of the airline in March 2021. There continues to be strong demand for air travel to and from the United Kingdom, particularly between the UK and the US which is the largest transatlantic market in the world. Norse is keen

Modus Therapeutics completes recruitment for Phase 1b LPS provocation study

STOCKHOLM, SWEDEN – September 27, 2022: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with major unmet medical needs, announces that recruitment has been completed into the company's clinical Phase 1b LPS provocation study evaluating the potential of its lead asset, sevuparin, for the treatment of sepsis and septic shock.The randomized, placebo-controlled Phase 1b study evaluates the effects of sevuparin on the symptoms of healthy volunteer participants who have been injected with the bacterial toxin lipopolysaccharide (LPS). Provocation

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 27 September 2022   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Lotta Haavisto Position: Closely associated person (1):Person Discharging Managerial Responsibilities In Issuer Name: Erkki Haavisto Position: Member of the Board Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 20041/6/6 ____________________________________________   Transaction date: 2022-09-26 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type:

BioStock: Arcede Pharma reports on the first quarter

After almost two months as a listed company, Arcede Pharma releases its first quarterly report. The first – and slightly shortened – quarter of the fiscal year has been marked by the spin-off from Respiratorius, but CEO Mia Lundblad also provides some operational updates. Among other things, she gives us some insight into the toxicological studies that are currently underway.Read the full article at biostock.se:https://www.biostock.se/en/2022/09/arcede-pharma-reports-on-the-first-quarter/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

NCC to build school and preschool in Turku

NCC has signed an agreement with the City of Turku to build the Suikkila school and a preschool in Turku. The assignment is a two-phase turnkey contract valued at approximately SEK 200 million. NCC was awarded the contract in the autumn of 2021, and since then has been working on the design and the planning for the school. The construction contract has now been signed, and construction can commence. The assignment includes the construction of an elementary school for grades 1–3, a preschool, a counseling center and premises for municipal activities. In addition, a sports hall

Enterprises gain clear path to CO2 reduction with Normative's guide

  Stockholm, September 27, 2022   Large businesses are one of the main contributors to global emissions. To accelerate work to reduce carbon emissions, Normative has published a new guide  explaining the essentials of carbon accounting for enterprises, from theory to best practices.   “Successfully navigating the rapidly-evolving carbon accounting space poses a big challenge to enterprises. Those that get it right will minimize risks, seize opportunities, and future-proof their businesses,” says Neil Ryland, CCO of Normative, the world’s

Lindex highlights the importance of examining your breasts regularly

With its campaign 'Support your Sisters', Lindex wants to highlight the importance of examining your breasts regularly and how important it is to support the research. Through strong portraits, the fashion company shows a close and honest portrait of women who have survived a cancer diagnosis thanks to research. During October, the fashion company will donate 10 percent of all bra sales to cancer research. "Our higher purpose - to empower and inspire women everywhere – is key in everything we do at Lindex. Joining forces with the Pink Ribbon campaign and contribute to the cause is

ExpreS2ion publishes investor video presentation

Hørsholm, Denmark, September 27, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at Aktiedagen Lund in which he presents provides an update on ExpreS2ion’s powerful technology platform for vaccine development, pipeline projects, and key financial figures, is now available on the company’s website.The presentation can be found on the Company’s investor website via the following link: https://investor.expres2ionbio.com/presentations/ Certified AdviserSvensk

Global AI software specialist Geoteric empowers geoscientists to choose how to interpret seismic data with two new neural networks in 2022.2

Geoteric, a world-leading provider of AI seismic interpretation software to the energy sector, has achieved an industry milestone by becoming the first supplier to bring six neural networks to market. The company has added two new neural networks, Acorn and Meranti, to its flagship AI Faults – 3D Networks module as part of a major update aimed at further enabling a better understanding of the subsurface.The AI Faults technology package, which reduces fault interpretation time by up to 95%, is used by over 40 customers worldwide to support business-critical decisions across the energy

Hexagon Ragasco, the world’s leading manufacturer of composite LPG cylinders, awarded new Environmental Product Declaration

Figure 1_System boundaries cradle to grave [Figure 1_System boundaries cradle to grave] Figure 1_System boundaries cradle to grave Hexagon Ragasco Cylinders [Illustration photo Hexagon Ragasco's cylinders] Illustration photo Hexagon Ragasco's cylinders Hexagon Ragasco, a Hexagon company and world leading manufacturer of LPG composite cylinders – was awarded a new Environmental Product Declaration (EPD)  from EPD-Norway covering the entire

UPM doubles the amount of deadwood in its forests to increase biodiversity

(UPM, Helsinki, 27 September 2022 at 10:00 EET) – UPM has set a target to increase the amount of deadwood in its commercial forests from the current level of about five cubic metres per hectare to ten cubic metres per hectare. In UPM's protected areas and commercial forests where a specific nature management target has been set, the deadwood target is 20 cubic metres per hectare. The new targets are part of UPM Forest Action, the UPM Forest Responsibility programme. In 2018, UPM set itself the target of increasing biodiversity in its forests in Finland while efficiently

Nomination Committee for Loomis’ Annual General Meeting 2023

The following representatives of Loomis AB’s shareholders will be members of the Nomination Committee for the Annual General Meeting 2023:   -        Elisabet Jamal Bergström, appointed by SEB Investment Management, Chairman of the Nomination Committee -        Bernard Horn, appointed by Polaris Capital Management, LLC -        Jacob Lundgren, appointed by Andra AP-fonden -        Elena Herrero, appointed by Indecap Fonder   The Chairman of the Board, Alf Göransson, has convened the Nomination Committee to its first meeting and has also been co-opted to the Nomination

BioStock Investor Meeting: Interview with Elicera Therapeutics

Elicera Therapeutics, led by CEO Jamal El-Mosleh, is developing immuno-oncology drug candidates based primarily on oncolytic viruses and CAR T-cells. The product portfolio includes four drug candidates and the company has also developed the technology platform iTANK. BioStock interviewed El-Mosleh about Elicera’s work at the BioStock Investor Meeting in Stockholm.See the full interview at biostock.se:https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-elicera-therapeutics/This is a press release from BioStock - Connecting Innovation & Capital. https://www.

Major investment in food and beverages at Stockholm Arlanda and Göteborg Landvetter – some 20 brand-new restaurants, bars and cafés to open starting in 2023

Swedavia continues to develop its range of services at Stockholm Arlanda Airport and Göteborg Landvetter Airport. The new marketplace at Arlanda will open starting in 2023 and is one of the biggest investments ever in food and beverage outlets at the airport. With the investment, Swedavia’s partner SSP will launch some 20 well-known food and beverage concepts that are brand-new to the airports. Other operators are expected to gradually set up additional food and beverage concepts. All of the concepts that SSP is launching are brand-new to the airports, and many of them will be part of

Alelion receives largest order to date – worth approximately MSEK 130

Alelion has received a major order for high-voltage battery systems from an existing European customer. The order, which is in EUR, with a total value of MSEK 130, will be delivered during Q1 – Q4 in 2023.“With this order, Alelion reach a higher utilization of its production capacity and it allows the company to implement more far-sighted plans regarding improved sourcing and tied capital efficiency”, says Åsa Nordström, CEO at Alelion. “With this order, Alelion secures its position in 2023 as a major supplier of lithium-Ion battery systems,” says Anders Dison, Director Marketing & Sales

First Episealer® Talus surgery performed in Israel

Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery in Israel with the ankle implant Episealer® Talus was successfully performed last week. Dr. Ezequiel Palmanovich performed the surgery at Meir Medical Center, assisted by Prof. Niek van Dijk with support from Episurf. Since previously, the Episealer® Knee technology is available in Israel. “We are pleased with adding an additional market as this was the first Episealer® Talus surgery in Israel“, says Pål Ryfors, CEO Episurf Medical. Prof. Niek van Dijk and the surgical team at Meir Medical Center,

Senior executives sell shares to finance the acquisition of shares through call options

Four senior executives are selling a total of 990 000 shares in MilDef Group. The sale is being made to finance the same persons’ acquisition of major shareholdings in the company based on previously issued call options.The senior executives are MilDef's CEO Björn Karlsson, CFO Daniel Ljunggren, Chief Sales Officer Fredrik Jacobsson, and the company's CTO Fredrik Persson. The transactions further strengthen MilDef's management's long-term ownership in MilDef with more extensive holdings and a larger number of senior executives with substantial ownership in the company. A number of

Cloetta updates on greenfield investment and confirms ambition to propose continued stable dividend

During today’s investor event, management will give an update on the plan to invest in a new greenfield facility in the Netherlands and close three existing plants. In addition to the previously communicated  annual EBIT delivery, Cloetta has quantified the value of enabled insourcing and long-term growth, as well as the net increase of capex as a result of the greenfield investment. Financing has been committed by Cloetta’s existing

BioStock Intestor Meeting: Interview with Redwood Pharma

Stockholmbased Redwood Pharma participated in the BioStock Investor Meeting in September where CEO Martin Vidaeus presented the company’s work. Afterwards, BioStock had the chance to interview Vidaeus who told us more about Redwood Pharma’s projects RP501 and RP101, aimed at the treatment of dry eyes.See the full interview at biostock.se:https://www.biostock.se/en/2022/09/biostock-intestor-meeting-interview-with-redwood-pharma/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Dignitana appoints Malin Isacsson to Head European Sales

Dignitana  announces that the Company has named Malin Isacsson as Vice President of Sales Europe. She begins her role immediately at the Company’s headquarters in Lund.  “Malin has proven success in solution sales for several leading MedTech companies in Europe and I am delighted that she has joined the Dignitana team. Her experience with both public and private healthcare are a valuable addition as we address the sales potential in markets across the EU and UK,” said Dignitana CEO Catarina Mård Löwenadler.  Most recently Malin worked at SoftPro Medical

Koselugo approved in Japan for NF1

27 September 2022 07:05 BST Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type 1 First medicine approved in Japan to treat this rare and debilitating genetic condition Pivotal SPRINT trial showed Koselugo reduced tumour volume Koselugo (selumetinib) has been approved in Japan for the treatment of paediatric patients three years of age and older with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms, such as pain and disfigurement, and PNs which cannot be completely removed by surgery

The last day for trading in the warrants of series TO 5 in Idogen AB is today, September 27, 2022

Today, September 27, 2022, is the last day for trading in warrants of series TO 5 (“Warrants”) in Idogen AB (“Idogen” or the “Company”). The subscription period for the Warrants runs until September 29, 2022. Three (3) Warrants gives the right to subscribe for one (1) new share in Idogen at a subscription price of SEK 0.77 per share.   If all Warrants are exercised for subscription of shares, Idogen will receive approximately MSEK 25.4 before issue costs. In order for the Warrants not to lapse without value, the holder must actively subscribe for shares no later than September 29,

Metso Outotec introduces visionary NextGen Pelletizing[TM] plant concept supporting transition to green steel

Metso Outotec Corporation’s press release on September 27, 2022, at 09:00 a.m. EESTMetso Outotec is launching NextGen Pelletizing™, a visionary concept for the next generation of pelletizing plants that strive to be carbon-neutral and autonomous. This revolutionary concept is a part of the company’s Planet Positive  offering focused on environmentally efficient technologies. “NextGen Pelletizing™ is yet further proof of our strong commitment to building innovative pelletizing solutions that are sustainable

Impilo divests leading haemostatic device developer and manufacturer Ferrosan Medical Devices to Danish consortium of long-term investors

Impilo AB (“Impilo”) and other minority investors, incl. Hans-Christian Bødker Jensen, have signed an agreement to divest the Danish medical devices company Ferrosan Medical Devices Group A/S (“FeMD”) to a consortium of Danish long-term investors consisting of Kirk Kapital, Lundbeckfonden and ATP (the “Consortium”).Impilo invested in FeMD in 2017 and has together with the management team realised the vision of creating a world leading medical devices group with product innovation and improved health outcomes at the core of its business. During Impilo’s ownership, revenues and EBITDA have

There are no items matching the current filter
There are no more items matching the current filter
Back to top